GT Biopharma Inc <GTBP.OQ> expected to post a loss of 64 cents a share - Earnings Preview

• GT Biopharma Inc GTBP.OQ GTBP.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025

• ​LSEG's mean analyst estimate for GT Biopharma Inc is for a loss of 64 cents per share.

• The one available analyst rating on the shares is "buy".

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for GT Biopharma Inc is $11.00​, above​ its last closing price of $2.27. ​​​

This summary was machine generated May 9 at 22:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)